unstable angina were enrolled in the study. Inclusion criteria were LDL cholesterol <3.4 mmol/l and C-reactive protein (CRP) <5 mg/l. Exclusion criteria were as follows: diabetes mellitus, any acute illness, known cancer, hepatic or renal dysfunction, anticoagulant therapy, acute coronary syndrome within 6 months before the start of the study, treatment for hyperlipidemia or with angiotensin converting enzymeinhibitors not later than 6 weeks preceding the enrollment. Patients taking aspirin or thienopyridines were also excluded. Given the data on abnormal fibrin structure in relatives of patients with premature MI 14 , we excluded individuals with MI or stroke among first-degree relatives.
All study participants received simvastatin (Zocor, Merck Sharp and Dohme) 40 mg/day on an open-label basis for 90 ±12 days.
The University Ethical Committee approved the study, and patients provided written, informed consent.
Laboratory investigations Blood samples were collected to 0.11 mol/L trisodium citrate (9:1, v/v) from all subjects at enrollment, and then at the end of simvastatin administration. Lipid profiles, glucose, creatinine, aminotransferases, and creatine kinase were assayed by routine laboratory techniques. Plasma and serum samples were centrifuged within 60 minutes at 20ºC and stored in aliquotes at −80ºC to allow batch analysis. Fibrinogen concentrations were determined using the Clauss method. High-sensitivity CRP levels were measured by an immunoturbidimetric method (Dade Behring). All the intra-assay coefficients of variation were below 7%.
Fibrin clot permeability Permeation properties of fibrin clots were investigated according to Mills et al. 14 in our modification 3, 13 . Briefly, 20 mmol/L calcium chloride and 1 U/mL human thrombin (Sigma) were added to citrated plasma. After 2 hours of incubation at room temperature in a wet chamber, tubes containing the clots were connected to a reservoir of a buffer (0.01 M Tris, 0.1 M NaCl, pH 7.5) and its volume flowing through the gels was measured within 60 minutes. Bromophenol blue was applied to the clot after experiments to detect potential leaks and defective clots were discarded. A permeation coefficient (K s ), which indicates the pore size, was calculated from the equation: K s = QxLxη/txAx∆p, where Q is the flow rate in time t, L is the length of a fibrin gel, η is the viscosity of liquid (in poise), A is the cross-sectional area (in cm 2 ), and ∆p is a differential pressure (in dyne/cm 2 ). The inter assay and intraassay variability of results was 7.2%.
Plasma clot formation and fibrinolysis Fibrinolysis by exogenous recombinant tissue plasminogen activator, rt-PA (Boerhinger Ingelheim), was evaluated using an assay developed by van dem Borne et al. 15 Briefly, citrated plasma was mixed (1:1) with HEPES buffer, containing calcium effects.
7 There is evidence that statins possess the so-called pleiotropic properties such as improved endothelial function, anti-inflammatory effects, and attenuation of blood coagulation, though their clinical relevance still generates controversy.
7-9 It has been reported that statins used for 3 or 28 days as well as 3 months can reduce thrombin formation and reactions catalyzed by this protease. 10 This effect is likely associated with drug-induced decrease in tissue factor expression, the major physio logical initiator of blood coagulation, which has been reported under various experimental conditions. 10 Recently, statins, but not aspirin, have been demonstrated to reduce risk of venous thrombosis in patients with a history of deep vein thrombosis and those who survived arterial cardiovascular events. 11, 12 In 2006, it was shown that simvastatin and atorvastatin were able to favorably alter fibrin clot structure and resistance to fibrinolysis in patients with coronary artery disease (CAD). 13 These unexpected effects of statins were associated with reduced thrombin formation, but not with cholesterol-lowering properties of these agents. 13 Fibrin-modifying properties of statins have also been demonstrated in high-risk patients during acute MI.
3 It is unknown whether in subjects at low risk of cardiovascular events with LDL cholesterol <3.4 mmol/l, statins can produce similar antithrombotic effects by modification of fibrin clot properties.
PAtIEnts And mEthods Men, aged <65 years, with no history of MI or hospitalization for Data are given as mean ±SD, unless otherwise stated.
Abbreviations: CRP -C-reactive protein, HDL-C -high-density lipoprotein cholesterol, LDL-C -low-density lipoprotein cholesterol, K s -clot permeability, t -clot lysis time, TC -total cholesterol used to test differences in continuous data between groups. The effect of simvastatin was analyzed using Wilcoxon signed rank test for non-normally distributed data, otherwise with paired t test. Pearson correlation coefficient was calculated to test the association between 2 variables. The level of significance was set at p <0.05. Simvastatin-induced increase in clot permeability showed significant associations only with decreases in CRP and total cholesterol as well as age (tAbLE 3). clot lysis Turbidimetric analysis of clot assembly and fibrinolysis revealed that clot lysis time was relatively long before the start of therapy and decreased significantly by 11.2% following therapy (tAbLE 1). A mean shortening in lysis time was 12.9 min (95% CI 10.3 to 15.5 min).
Posttreatment lysis time showed similar associations (tAbLE 2, PAnEL b) .
Analysis of associations between simvastatin-induced changes in the laboratory para meters (tAbLE 3) showed that the magnitude of decreases in lysis time is associated with changes in serum CRP levels. Moreover there was a significant correlation between increases in lysis time and reduction in triglycerides observed following simvastatin administration. Other laboratory variables showed no associations with the changes in lysis time (tAbLE 3). multiple regression analysis To identify variables that are independently associated with fibrin clot variables, the multiple regression analysis was chloride, diluted recombinant tissue factor (Innovin, Dade Behring), phospholipid vesicles, prepared as described 16 , and rt-PA (Boerhinger Ingelheim). This mixture (100 µL) was transferred to a microtiter reader and turbidity was measured at 405 nm at 37°C in a Spectramax 340 kinetic microplate reader (Molecular Devices Corp., Menlo Park, CA). Clot lysis time was defined as the time from the midpoint of the baseline clear to maximum turbid transition, to the final plateau phase. The inter assay and intraassay coefficients of variation were 8.1 and 6.2%, respectively. statistical analysis Data are expressed as mean (±SD) or otherwise stated. Categorical values were compared using the χ 2 test, and paired t test was In the present study higher CRP levels at baseline were also associated with lower clot permeability and longer clot lysis. A pathophysio logic basis for these relationships is the in vitro study by Salonen and coworkers 20 showing that CRP binds to various proteins including fibrin(ogen). Our findings clearly indicate that at lower cholesterol levels and less enhanced low-grade inflammatory state typical of atherosclerosis, fibrin-modifying properties of simvastatin are more pronounced and might largely contribute to its antithrombotic effects demonstrated both in arterial and venous thrombotic disorders of high prevalence in the general population.
In contrast to Fatah et al., 21 we failed to find significant associations between any lipid variables and clot permeability with one exception. Reduction in triglycerides following simvastatin showed association with lysis time, but not clot permeability. No such correlations were found in high-risk patients, in the stable and acute phase of CAD. 3,13 Differences in patient population characteristics might be a reason for this discrepancy.
Our study has several limitations. First, the number of the patients enrolled was limited and the study was open-label with no control group receiving placebo or no treatment. However, all other factors known to affect fibrin properties remained unaltered following a 3-month statin therapy. Therefore the postreatment changes in clot properties are most likely associated with the inter vention alone. Second, our analysis was restricted to two major fibrin variables. Other features have not been evaluated. Third, homocysteine and lipoprotein(a), which can alter fibrin properties [22] [23] [24] , have not been determined in this study. However, there is no consistent evidence showing reduced levels of both variables as a result of simvastatin treatment. Fourth, effects of statins on clot features have not been documented by means of other methods, e.g. using scanning electron microscopy. Fiber thickness and pore size estimated using this technique usually showed strong correlations with permeability and turbidimetric analysis of clot formation. 4 On the other hand, using this technique, clots are fixed and further processed, therefore measurements are hard to be extrapolated to the in vivo situation, which was supported, for example, by inconclusive data from electron microscopy in patients on peritoneal dialysis. 25 Fifth, since diabetic subjects were excluded, it is unclear whether similar effects of simvastatin could be observed in individuals with no clinically overt CAD, having average LDL cholesterol levels and suffering from diabetes type 2. This common disease markedly alters fibrin clot structure and function as shown by Robert Ariëns' group 6 , therefore most likely statins will not modify these features potently enough to be detectable using our approach, which might explain doubts surrounding the issue of statin use in diabetics. 26 Finally, our experimental approach did not allow to analyze performed. As shown in tAbLE 4, simvastatin-induced increase in clot permeability was associated only with age and decrease in CRP levels (R 2 for the model = 0.61), while shortening of clot lysis time observed following simvastatin use was predicted only by reduction of triglycerides and CRP (R 2 for the model = 0.62).
dIscussIon The current study demonstrates that simvastatin used commonly in atherosclerotic vascular disease can favorably affect plasma clot architecture in low-risk subjects. Our data provide evidence that statin-induced slightly, but significantly faster lysis, indicating more effective lysis of the plasma clots formed, is linked with the formation of clots with loosely packed fibers, characterized by greater permeability. We observed significant increases in clot permeability following 90 ±12 days of therapy with simvastatin 40 mg/d. Interestingly, the magnitude of these effects was associated with the magnitude of reduction in serum CRP concentrations, but not cholesterol-lowering actions of simvastatin. The formation of more porous and lysable fibrin clots during treatment with statins represents their novel mechanism of action associated with suppression of inflammation that may have clinical implications in all thrombotic disorders.
In 2004, Scott et al. 6 suggested that the use of some medications such as fibrates might lead to the formation of more porous clots because of reduced fibrinogen levels. Inconsistent reports on statin-induced changes in fibrinogen levels were also published. [17] [18] [19] In the present study, simvastatin did not lower fibrinogen levels, therefore, the changes in clot permeability are not related to this variable. In 2006, Undas et al. 13 demonstrated favorable effects of reduced CRP on fibrin clot permeability, but not clot lysis, in high-risk subjects. Importantly, in patients with LDL cholesterol <3.4 mmol/l and CRP <5 mg/l, we observed significant associations between changes in both fibrin variables and decreases in serum CRP levels. the effect of blood cells and platelets on fibrin clot structure/function, which can markedly alter for example fibrinolysis. 27 In conclusion, our results suggest that in normocholesterolemic subjects with no evidence of enhanced inflammation, statins increase plasma clot permeability following a 3-month therapy, and these effects are unrelated to any changes in fibrinogen levels. Importantly, improved permeability is associated with significant acceleration of clot lysis. These additional antithrombotic mechanisms reported here can in part account for reduction in thrombotic complications of atherosclerosis in patients treated with statins, together with other thrombin lowering associated effects that have been convincingly demonstrated for simvastatin.
28 To what extent altered fibrin structure and function with the resultant increased clot lysability may contribute to clinical benefits of statins in arterial and venous thrombosis, remains to be established. Abbreviations: see tAbLEs 1 and 2
